Journal of Medicinal Chemistry · 2008 · 71 citations · 23 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAnalgesic PharmacologyCannabinoid PharmacologyHeterocyclic ChemistryLigand BindingReceptor PharmacologyStructure-activity Relationship AnalysisCannabinoid AgonistsCannabinoid AnalgesicsCannabinoid Receptor PharmacologyCannabinoid Structure-activity RelationshipsLigand-receptor AffinityMedicinal HeterocyclesSelectivitySteric Properties
Quinolone-3-carboxamides 11 bearing at position 5, 6, 7, or 8 diverse substituents such as halides, alkyl, aryl, alkoxy, and aryloxy groups differing in their steric/electronic properties, were prepared. The new compounds were tested in vitro for CB1 and CB2 receptor affinity in comparison with the reference compounds rimonabant and SR144528. The tested compounds exhibited CB2 affinity in the range from 55.9 to 0.8 nM and CB1 affinity in the range from >10,000 to 5.3 nM, with selectivity indeces [Ki(CB1)/Ki(CB2)] varying from >2666.6 to 1.23. On the basis of the structure-selectivity relationship developed, the presence of a substituent at C6/C8 or C7 well accounts for the high or low CB2 selectivity, respectively. Compound 11c, characterized by high CB2 affinity and selectivity, showed analgesic activity in the formalin test of acute peripheral and inflammatory pain in mice as a result of selective CB2 agonistic activity.
23
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Murielle Rinaldi‐Carmona, Francis Barth, Michel Héaulme et al. · FEBS Letters · 1994 · 1.8K citations · Full text
Medicine, Neuroscience, Pharmacology +14
Peripheral cannabinoid receptor, CB2, regulates bone mass
Orr Ofek, Meliha Karsak, Nathalie Leclerc et al. · Proceedings of the National Academy of Sciences · 2006 · 531 citations · Full text